Disclosed are processes for producing cultured dairy products, such as yogurt, that are shelf-stable without refrigeration. Such processes can include contacting a milk base having from 0.5 to 1.9 wt. % milk sugar with a lactic acid bacteria culture and aseptically packaging in a container, followed by storage under conditions suitable to result in a pH of less than 4.7.

An object of one present invention is to provide a food composition including, as an active ingredient thereof, Lactobacillus mucosae that has a function of improving a gut microbiota. An object of another present invention is to provide an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof. The one present invention provides a composition for improving the gut microbiota, including the bacterial cell or a culture of Lactobacillus mucosae as an active ingredient thereof. The other present invention provides an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof.

An object of the present invention is to provide a fermented milk and polysaccharide capable of inhibiting cancerous cachexia. A fermented milk with cancerous cachexia inhibitory effect according to one aspect of the present invention contains Lactobacillus delbrueckii subsp. bulgaricus as an active ingredient. Also, polysaccharide with cancerous cachexia inhibitory effect according to another aspect of the present invention are produced from the Lactobacillus delbrueckii subsp. bulgaricus. It is preferable that the Lactobacillus delbrueckii subsp. bulgaricus is Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (accession number: FERM BP-10741).

The present invention is in the field of dairy technology. It relates to methods for producing fermented milk products, characterized the bacterium Lactobacillus rhamnosus DSM 33515 or mutants obtainable therefrom is used. Lactobacillus rhamnosus bacteria DSM 33515 has low post-acidification in fermented milk products and can provide antimicrobial effects. The invention also provides Lactobacillus rhamnosus DSM 33515 or mutants obtainable therefrom as well as related compositions.

The present disclosure relates to processes for producing antihypertensive peptide compositions from milk compositions. It also relates to peptide compositions producible by the processes, as well as dosage forms, food products, supplements, powdered milk formula and beverages containing the peptide compositions, and to therapeutic methods and uses of the peptide compositions.

Disclosed are processes for producing high protein, Greek yogurt products. Such processes can include a step of concentrating a skim milk product to produce a protein-enriched milk fraction, which then can be combined with one or more additional milk fractions to form a yogurt base. The yogurt base is inoculated with a yogurt culture and fermented, and at least a portion of the acid whey is removed from the fermented product using a ceramic ultrafiltration membrane system to form the Greek yogurt product.

The present disclosure relates to a method for preparing an aglycone or hydrolyzed glycoside converted from a glycoside and, specifically, to a method for preparing an aglycone or hydrolyzed glycoside from a glycoside by converting a glycoside into an aglycone form or hydrolyzed glycoside by using a microorganism producing β-glycosidase, and then recovering the aglycone or hydrolyzed glycoside accumulated in the cells of the microorganism.

A fermentation of a milk source with Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4404) or a Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4405) to form a fermented milk product. The fermented milk product has at least a cream flavour and aroma. The fermented milk product can be in the form of a powder or a concentrate. The fermented milk product has applications in the food industry. A use of a lactic acid bacterium, Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4404) or a Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4405) for the manufacture of butter-cream flavouring milk ingredients containing at least one of diacetyl, acetoin and 3,4-dihydroxy-3,4-dimethyl-2,5-hexanedione.

Disclosed is a novel lactic acid bacterium belonging to Lactobacillus plantarum, which has an excellent fermentative ability affording high achievable cell counts even if various vegetable or fruit juices are used as fermentative substrates. The lactic acid bacterium belonging to Lactobacillus plantarum is characterized by the achievable viable cell counts being 10.sup.8 CFU/ml or more in both cases when 100% juice of grape or of orange is used as fermentative substrate.

A new use of Lactobacillus paracasei subsp. paracasei K56 capable of regulating the gastrointestinal flora balance is described. The deposit number of the Lactobacillus paracasei subsp. paracasei is DSM27447. This strain alone has the ability to significantly promote the growth of intestinal Bifidobacterium and Lactobacillus, suppress Desulfovibrio and/or Enterobacteria in the intestine, suppress Helicobacter and/or Escherichia-Shigella, and can endure a simulated in vitro gastrointestinal fluid stress environment. Experiments in mice show that this strain has no acute oral toxicity, no antibiotic resistance, and may be safely used in food processing.